Celon Pharma Announces Results of Phase II clinical trial for CPL’ 116, a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA)
KIELPIN, Poland, June 17, 2024 (GLOBE NEWSWIRE) — Celon Pharma S.A. (CLN.WA) today announced the successful completion of a Phase…
